Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis
You may also be interested in...
Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk
FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia
From Verus to Meritage: A Biotech Prototype for Tough Economic Times
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.
Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.